Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
Status:
Terminated
Trial end date:
2011-05-19
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn about the effects of the drug, lenalidomide (Revlimid®),
on neuropathy (damage to the nerves that affect feelings and strength) associated with
Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS).